158 related articles for article (PubMed ID: 28973822)
21. HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes.
Johansson L; Snäll J; Sendi P; Linnér A; Thulin P; Linder A; Treutiger CJ; Norrby-Teglund A
Front Cell Infect Microbiol; 2014; 4():4. PubMed ID: 24524027
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections.
Johansson L; Linnér A; Sundén-Cullberg J; Haggar A; Herwald H; Loré K; Treutiger CJ; Norrby-Teglund A
J Immunol; 2009 Sep; 183(6):4047-54. PubMed ID: 19717514
[TBL] [Abstract][Full Text] [Related]
23. The virulence factors of group A streptococcus strains isolated from invasive and non-invasive infections in Polish and German centres, 2009-2011.
Strus M; Heczko PB; Golińska E; Tomusiak A; Chmielarczyk A; Dorycka M; van der Linden M; Samet A; Piórkowska A
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1643-1649. PubMed ID: 28401320
[TBL] [Abstract][Full Text] [Related]
24. [Necrotizing fasciitis. A rapid fatal course of Streptococcus pyogenes, Lancefield group A serotype M1 (killer streptococci), infection].
Pedersen HS; Martinsen KR
Ugeskr Laeger; 1991 Oct; 153(42):2955. PubMed ID: 1949324
[TBL] [Abstract][Full Text] [Related]
25. Hypervariability generated by natural selection in an extracellular complement-inhibiting protein of serotype M1 strains of group A Streptococcus.
Stockbauer KE; Grigsby D; Pan X; Fu YX; Mejia LM; Cravioto A; Musser JM
Proc Natl Acad Sci U S A; 1998 Mar; 95(6):3128-33. PubMed ID: 9501227
[TBL] [Abstract][Full Text] [Related]
26. Management of Contacts of Patients With Severe Invasive Group A Streptococcal Infection.
de Almeida Torres RS; dos Santos TZ; Torres RA; Petrini LM; Burger M; Steer AC; Smeesters PR
J Pediatric Infect Dis Soc; 2016 Mar; 5(1):47-52. PubMed ID: 26908491
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of necrotizing infection caused by Staphylococcus aureus and Streptococcus pyogenes at an Iowa hospital.
Thapaliya D; O'Brien AM; Wardyn SE; Smith TC
J Infect Public Health; 2015; 8(6):634-41. PubMed ID: 26163423
[TBL] [Abstract][Full Text] [Related]
28. Determination of the relationship between group A streptococcal genome content, M type, and toxic shock syndrome by a mixed genome microarray.
Vlaminckx BJ; Schuren FH; Montijn RC; Caspers MP; Fluit AC; Wannet WJ; Schouls LM; Verhoef J; Jansen WT
Infect Immun; 2007 May; 75(5):2603-11. PubMed ID: 17325055
[TBL] [Abstract][Full Text] [Related]
29. Local activation of coagulation factor XIII reduces systemic complications and improves the survival of mice after Streptococcus pyogenes M1 skin infection.
Deicke C; Chakrakodi B; Pils MC; Dickneite G; Johansson L; Medina E; Loof TG
Int J Med Microbiol; 2016 Nov; 306(7):572-579. PubMed ID: 27338836
[TBL] [Abstract][Full Text] [Related]
30. Label-free proteomic analysis of environmental acidification-influenced Streptococcus pyogenes secretome reveals a novel acid-induced protein histidine triad protein A (HtpA) involved in necrotizing fasciitis.
Wen YT; Wang JS; Tsai SH; Chuan CN; Wu JJ; Liao PC
J Proteomics; 2014 Sep; 109():90-103. PubMed ID: 24998435
[TBL] [Abstract][Full Text] [Related]
31. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections.
The Editors
J Med Microbiol; 2000 Oct; 49(10):849-852. PubMed ID: 11023181
[No Abstract] [Full Text] [Related]
32. Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection.
Hoe NP; Vuopio-Varkila J; Vaara M; Grigsby D; De Lorenzo D; Fu YX; Dou SJ; Pan X; Nakashima K; Musser JM
J Infect Dis; 2001 Feb; 183(4):633-9. PubMed ID: 11170990
[TBL] [Abstract][Full Text] [Related]
33. M1 protein allows Group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition.
Lauth X; von Köckritz-Blickwede M; McNamara CW; Myskowski S; Zinkernagel AS; Beall B; Ghosh P; Gallo RL; Nizet V
J Innate Immun; 2009; 1(3):202-14. PubMed ID: 20375578
[TBL] [Abstract][Full Text] [Related]
34. Molecular insight into invasive group A streptococcal disease.
Cole JN; Barnett TC; Nizet V; Walker MJ
Nat Rev Microbiol; 2011 Sep; 9(10):724-36. PubMed ID: 21921933
[TBL] [Abstract][Full Text] [Related]
35. Group A streptococcus.
Martin JM; Green M
Semin Pediatr Infect Dis; 2006 Jul; 17(3):140-8. PubMed ID: 16934708
[TBL] [Abstract][Full Text] [Related]
36. Immunity to group a streptococcal M proteins: forging a single-edged sword.
Madoff LC
Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
[No Abstract] [Full Text] [Related]
37. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
[TBL] [Abstract][Full Text] [Related]
38. STAT3-dependent CXC chemokine formation and neutrophil migration in streptococcal M1 protein-induced acute lung inflammation.
Zhang S; Hwaiz R; Luo L; Herwald H; Thorlacius H
Am J Physiol Lung Cell Mol Physiol; 2015 Jun; 308(11):L1159-67. PubMed ID: 25840996
[TBL] [Abstract][Full Text] [Related]
39. M1 protein-dependent intracellular trafficking promotes persistence and replication of Streptococcus pyogenes in macrophages.
Hertzén E; Johansson L; Wallin R; Schmidt H; Kroll M; Rehn AP; Kotb M; Mörgelin M; Norrby-Teglund A
J Innate Immun; 2010; 2(6):534-45. PubMed ID: 20798480
[TBL] [Abstract][Full Text] [Related]
40. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
